A Phase 3 open label randomized multicenter trial to assess the efficacy and safety of the dispersible arterolane maleate 37.5 mg and piperaquine phosphate (PQP) 187.5 mg tablets in comparison with Coartem dispersible in pediatric patients with acute uncomplicated Plasmodium falciparum malaria

Trial Profile

A Phase 3 open label randomized multicenter trial to assess the efficacy and safety of the dispersible arterolane maleate 37.5 mg and piperaquine phosphate (PQP) 187.5 mg tablets in comparison with Coartem dispersible in pediatric patients with acute uncomplicated Plasmodium falciparum malaria

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs Arterolane/piperaquine (Primary) ; Artemether/lumefantrine
  • Indications Malaria
  • Focus Registrational; Therapeutic Use
  • Sponsors Sun Pharmaceutical Industries
  • Most Recent Events

    • 19 Oct 2017 New trial record
    • 29 Aug 2017 Results published in the Clinical Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top